PE20061310A1 - Forma cristalina de la sal clorhidrato de 1-isopropil-2-oxo-1,2-dihidroquinolina-3-acido carboxilico {(1s,3r,5r)-8-[(r)-2-hidroxi-3-(metanosulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida - Google Patents

Forma cristalina de la sal clorhidrato de 1-isopropil-2-oxo-1,2-dihidroquinolina-3-acido carboxilico {(1s,3r,5r)-8-[(r)-2-hidroxi-3-(metanosulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida

Info

Publication number
PE20061310A1
PE20061310A1 PE2006000360A PE2006000360A PE20061310A1 PE 20061310 A1 PE20061310 A1 PE 20061310A1 PE 2006000360 A PE2006000360 A PE 2006000360A PE 2006000360 A PE2006000360 A PE 2006000360A PE 20061310 A1 PE20061310 A1 PE 20061310A1
Authority
PE
Peru
Prior art keywords
dihydroquinoline
azabicyclo
oxo
oct
propyl
Prior art date
Application number
PE2006000360A
Other languages
English (en)
Spanish (es)
Inventor
Paul R Fatheree
Adam A Goldblum
Daniel Genov
S Derek Turner
Robert Chao
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of PE20061310A1 publication Critical patent/PE20061310A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2006000360A 2005-04-06 2006-04-03 Forma cristalina de la sal clorhidrato de 1-isopropil-2-oxo-1,2-dihidroquinolina-3-acido carboxilico {(1s,3r,5r)-8-[(r)-2-hidroxi-3-(metanosulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida PE20061310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06

Publications (1)

Publication Number Publication Date
PE20061310A1 true PE20061310A1 (es) 2007-01-23

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000360A PE20061310A1 (es) 2005-04-06 2006-04-03 Forma cristalina de la sal clorhidrato de 1-isopropil-2-oxo-1,2-dihidroquinolina-3-acido carboxilico {(1s,3r,5r)-8-[(r)-2-hidroxi-3-(metanosulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida

Country Status (29)

Country Link
US (4) US7728004B2 (OSRAM)
EP (1) EP1874766B1 (OSRAM)
JP (2) JP5230407B2 (OSRAM)
KR (1) KR101322873B1 (OSRAM)
CN (1) CN101151264B (OSRAM)
AR (2) AR053208A1 (OSRAM)
AT (1) ATE479682T1 (OSRAM)
AU (1) AU2006232129B2 (OSRAM)
BR (1) BRPI0610657A2 (OSRAM)
CA (1) CA2603654C (OSRAM)
CY (1) CY1111275T1 (OSRAM)
DE (1) DE602006016586D1 (OSRAM)
DK (1) DK1874766T3 (OSRAM)
EA (1) EA012115B1 (OSRAM)
ES (1) ES2350495T3 (OSRAM)
HR (1) HRP20100629T1 (OSRAM)
IL (1) IL186023A (OSRAM)
MA (1) MA29403B1 (OSRAM)
MX (1) MX2007012438A (OSRAM)
MY (1) MY151075A (OSRAM)
NO (1) NO339699B1 (OSRAM)
NZ (1) NZ561900A (OSRAM)
PE (1) PE20061310A1 (OSRAM)
PL (1) PL1874766T3 (OSRAM)
PT (1) PT1874766E (OSRAM)
SI (1) SI1874766T1 (OSRAM)
TW (1) TWI377206B (OSRAM)
WO (1) WO2006108127A2 (OSRAM)
ZA (1) ZA200708071B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
ATE431824T1 (de) 2004-11-05 2009-06-15 Theravance Inc Chinolinon-carboxamid-verbindungen
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
US20080287486A1 (en) * 2007-05-17 2008-11-20 Theravance, Inc. Prokinetic agent for bowel preparation
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
NZ614151A (en) * 2007-12-07 2015-04-24 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
HUE038141T2 (hu) * 2009-04-13 2018-10-29 Theravance Biopharma R&D Ip Llc 5-HT4 receptor agonisták és acetilkolinészteráz inhibitorok kombinációi kognitív rendellenességek kezelésére
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
ES3017582T3 (en) 2010-04-07 2025-05-13 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
CN105848657B (zh) 2013-11-12 2020-05-22 沃泰克斯药物股份有限公司 制备用于治疗cftr介导的疾病的药物组合物的方法
SI3661518T1 (sl) * 2017-07-31 2025-01-31 Alfasigma S.P.A. Načini zdravljenja simptomov gastropareze z zdravilom velusetrag
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
JP2025533507A (ja) 2022-09-20 2025-10-07 アルファシグマ ソシエタ ペル アチオニ 慢性偽性腸閉塞症(cipo)の治療に使用するためのベルセトラグ

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
CA2097815C (en) 1990-12-28 2001-04-17 Fumio Suzuki Quinoline derivative
EP0670319A4 (en) 1992-11-20 1996-01-17 Thaisho Pharmaceutical Co Ltd HETEROCYCLIC COMPOUNDS.
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
WO2005049608A1 (en) 2003-11-24 2005-06-02 Pfizer Japan, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
ATE441646T1 (de) 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
ATE431824T1 (de) 2004-11-05 2009-06-15 Theravance Inc Chinolinon-carboxamid-verbindungen
JP2008530225A (ja) 2005-02-17 2008-08-07 セラヴァンス, インコーポレーテッド インダゾール−カルボキサミド化合物の結晶型
WO2006094063A1 (en) 2005-03-02 2006-09-08 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
NO20075574L (no) 2007-11-02
KR101322873B1 (ko) 2013-10-30
HRP20100629T1 (hr) 2010-12-31
PT1874766E (pt) 2010-11-30
JP5230407B2 (ja) 2013-07-10
BRPI0610657A2 (pt) 2010-07-13
CN101151264A (zh) 2008-03-26
EA200702161A1 (ru) 2008-04-28
EP1874766A2 (en) 2008-01-09
IL186023A (en) 2011-09-27
PL1874766T3 (pl) 2011-02-28
EA012115B1 (ru) 2009-08-28
MA29403B1 (fr) 2008-04-01
EP1874766B1 (en) 2010-09-01
AR110019A2 (es) 2019-02-13
JP2012153725A (ja) 2012-08-16
IL186023A0 (en) 2008-01-20
TW200643020A (en) 2006-12-16
CA2603654A1 (en) 2006-10-12
ATE479682T1 (de) 2010-09-15
AU2006232129A1 (en) 2006-10-12
WO2006108127A3 (en) 2007-01-04
DE602006016586D1 (de) 2010-10-14
US7728004B2 (en) 2010-06-01
US20160095849A1 (en) 2016-04-07
HK1110866A1 (en) 2008-07-25
US20100197728A1 (en) 2010-08-05
CA2603654C (en) 2014-05-27
US20140256769A1 (en) 2014-09-11
US9126994B2 (en) 2015-09-08
NZ561900A (en) 2010-12-24
NO339699B1 (no) 2017-01-23
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
AR053208A1 (es) 2007-04-25
WO2006108127A2 (en) 2006-10-12
TWI377206B (en) 2012-11-21
CN101151264B (zh) 2011-07-06
ZA200708071B (en) 2008-10-29
AU2006232129B2 (en) 2012-07-12
US20060229332A1 (en) 2006-10-12
CY1111275T1 (el) 2015-08-05
KR20070116988A (ko) 2007-12-11
DK1874766T3 (da) 2010-12-06
JP2008535848A (ja) 2008-09-04
SI1874766T1 (sl) 2010-12-31
ES2350495T3 (es) 2011-01-24
MY151075A (en) 2014-03-31
MX2007012438A (es) 2007-12-05

Similar Documents

Publication Publication Date Title
PE20061310A1 (es) Forma cristalina de la sal clorhidrato de 1-isopropil-2-oxo-1,2-dihidroquinolina-3-acido carboxilico {(1s,3r,5r)-8-[(r)-2-hidroxi-3-(metanosulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida
PE20081258A1 (es) ANTICUERPOS ANTI-hTNFALFA CRISTALINOS
ES2411604T3 (es) Compuestos orgánicos
UA107174C2 (uk) Кристалічні форми саксагліптину та процес їх одержання (варіанти)
PE20001333A1 (es) Proceso para estabilizar macrolidos de polieno
PE20120599A1 (es) Metodo para producir material de sabor
WO2007087453A3 (en) Compositions and methods for treating haematological proliferative disorders
AR059087A1 (es) Derivados de pirimidina como inhibidores de pi-3 quinasa , uso de los mismos y composiciones farmaceuticas.
CN101230062A (zh) 蕈毒碱性乙酰胆碱受体拮抗剂
CR9748A (es) Derivados de xantina como agonistas selectivos de hm74a
ES2676600T3 (es) Fabricación y uso de ARN monocatenario sintetizado in vitro para la introducción en células de mamífero para inducir un efecto biológico o bioquímico
CR10874A (es) Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3 metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro benzonitrilo y metodos para el uso de los mismos
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
AR064645A1 (es) Proceso para la preparacion de derivados del acido 2-amino-5-cianobenzoico
BRPI0915417B8 (pt) derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina
UY28039A1 (es) Granulados de meloxicam solubles en agua
BRPI0520252A2 (pt) método de desacilar sucralose-6-éster
BRPI0809942B8 (pt) processos de preparação de porfirinas, pirrometanos e compostos intermediários
AR058728A1 (es) Derivados de aril-isoxazol-4-il-imidazo[1,5-a]piridina, metodo de preparacion,medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos.
BRPI0802215A2 (pt) mÉtodo de fabricaÇço de uma espuma de aspersço de poliisocianurato/poliuretano
PE20090192A1 (es) Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo
AR055761A1 (es) Procedimiento para preparar especies de aluminio
AR057291A1 (es) Proceso para la preparacion de acidos bisfosfonicos geminales y las sales y/o hidratos farmaceuticamente aceptables de los mismos, una composicion farmaceutica que los contiene y el uso de esta en el tratamiento de la osteoporosis
WO2006122769A3 (de) Substituierte spiro-verbindungen und deren verwendung zur herstellung von arzneimitteln gegen schmerz
WO2007083243A3 (en) An improved process for the preparation of risedronate sodium hemi-pentahydrate

Legal Events

Date Code Title Description
FC Refusal